This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Clinical Trial

. 1997 Oct;63(4):547.

doi: 10.1136/jnnp.63.4.547.

Moclobemide and selegeline in the treatment of depression in Parkinson's disease

E N Steur, L A Ballering

PMID: 9343144
PMCID: PMC2169782
DOI: 10.1136/jnnp.63.4.547

Clinical Trial

Moclobemide and selegeline in the treatment of depression in Parkinson's disease

E N Steur et al. J Neurol Neurosurg Psychiatry. 1997 Oct.

. 1997 Oct;63(4):547.

doi: 10.1136/jnnp.63.4.547.

Authors

E N Steur, L A Ballering

PMID: 9343144
PMCID: PMC2169782
DOI: 10.1136/jnnp.63.4.547

No abstract available

PubMed Disclaimer

Similar articles

Moclobemide for depression.
[No authors listed] [No authors listed] Drug Ther Bull. 1994 Jan 20;32(1):6-8. Drug Ther Bull. 1994. PMID: 7635005
Moclobemide and the reversible inhibitors of monoamine oxidase antidepressants.
Priest RG. Priest RG. Acta Psychiatr Scand Suppl. 1990;360:39-41. doi: 10.1111/j.1600-0447.1990.tb05322.x. Acta Psychiatr Scand Suppl. 1990. PMID: 2248065 Clinical Trial. No abstract available.
Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson's disease.
Jansen Steur EN, Ballering LA. Jansen Steur EN, et al. Adv Neurol. 1999;80:505-8. Adv Neurol. 1999. PMID: 10410764 Clinical Trial. No abstract available.
[Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
Volz HP, Gleiter CH, Möller HJ. Volz HP, et al. Nervenarzt. 1996 May;67(5):339-47. Nervenarzt. 1996. PMID: 9005342 Review. German.
The advent of selective monoamine oxidase A inhibitor antidepressants devoid of the cheese reaction.
Youdim MB. Youdim MB. Acta Psychiatr Scand Suppl. 1995;386:5-7. doi: 10.1111/j.1600-0447.1995.tb05917.x. Acta Psychiatr Scand Suppl. 1995. PMID: 7717095 Review. No abstract available.

See all similar articles

Cited by

Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset.
Hamadjida A, Nuara SG, Frouni I, Kwan C, Bédard D, Gourdon JC, Huot P. Hamadjida A, et al. Naunyn Schmiedebergs Arch Pharmacol. 2020 Nov;393(11):2139-2144. doi: 10.1007/s00210-020-01927-w. Epub 2020 Jun 29. Naunyn Schmiedebergs Arch Pharmacol. 2020. PMID: 32601846
Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies.
Naoi M, Maruyama W, Shamoto-Nagai M. Naoi M, et al. Int J Mol Sci. 2022 Sep 21;23(19):11059. doi: 10.3390/ijms231911059. Int J Mol Sci. 2022. PMID: 36232361 Free PMC article. Review.
Psychiatric aspects of Parkinson's disease--an update.
Schrag A. Schrag A. J Neurol. 2004 Jul;251(7):795-804. doi: 10.1007/s00415-004-0483-3. J Neurol. 2004. PMID: 15258780 Review.
MAO-inhibitors in Parkinson's Disease.
Riederer P, Laux G. Riederer P, et al. Exp Neurobiol. 2011 Mar;20(1):1-17. doi: 10.5607/en.2011.20.1.1. Epub 2011 Mar 31. Exp Neurobiol. 2011. PMID: 22110357 Free PMC article.
Dopaminergic Therapies for Non-motor Symptoms in Parkinson's Disease.
Schaeffer E, Berg D. Schaeffer E, et al. CNS Drugs. 2017 Jul;31(7):551-570. doi: 10.1007/s40263-017-0450-z. CNS Drugs. 2017. PMID: 28643183 Review.

See all "Cited by" articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information